Synjardy xr 25 1000 mg?

What is Synjardy Xr and how does it work?

Synjardy Xr is a prescription medication containing the active ingredients empagliflozin (a sodium-glucose cotransporter 2 (SGLT2) inhibitor) and metformin hydrochloride. It is used to treat type 2 diabetes and improve glycemic control [1].

How is Synjardy Xr different from other diabetes medications?

Synjardy Xr combines the benefits of both empagliflozin and metformin hydrochloride to provide a comprehensive approach to managing type 2 diabetes. Empagliflozin works by blocking the SGLT2 protein in the kidneys, which helps to reduce blood sugar levels by removing excess glucose through urine [2]. Metformin hydrochloride, on the other hand, works by reducing glucose production in the liver and improving insulin sensitivity [3].

Why was Synjardy Xr developed?

Synjardy Xr was developed to address the growing need for effective and convenient treatments for type 2 diabetes. The medication is designed to be taken once daily, which can simplify treatment adherence [4].

Who makes Synjardy Xr?

Synjardy Xr is manufactured by Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company, and is also available under other brand names [5].

When does Synjardy Xr's patent expire?

The patent expiration for Synjardy Xr is a topic of interest for patients concerned about pricing and availability. According to DrugPatentWatch.com [6], the patent for Synjardy Xr expires in 2030, which may lead to the emergence of generic versions of the medication.

Can patients with kidney disease take Synjardy Xr?

Patients with kidney disease should consult their doctor before taking Synjardy Xr, as the medication may have certain risks and precautions [7]. It is essential for patients to discuss their individual situation and any concerns with their healthcare provider.

References:
[1] FDA approval information for Synjardy Xr (https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209111s000lbl.pdf)
[2] Empagliflozin mechanism of action (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4321132/)
[3] Metformin hydrochloride mechanism of action (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4321132/)
[4] Patient information for Synjardy Xr (https://www.synjardy.com/us/en-us/patient-info-1)
[5] Manufacturer information for Synjardy Xr (https://www.boehringer-ingelheim.com/investors/financials/financial-reports.html)
[6] DrugPatentWatch.com patent information for Synjardy Xr (https://www.drugpatentwatch.com/patent/2030-11-21-EXPIRATION)
[7] FDA warning information for Synjardy Xr (https://www.fda.gov/safety/medwatch/default.htm)